Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Från apotekare till poddare – Magnus Lejelöv har rösten som verktyg

Magnus Lejelöv har över 20 års erfarenhet från läkemedelssektorn och har intervjuat nära två hundra vårdprofiler i sina poddar. I maj står han på scenen i Lund ...

Thomas Eldered: ”Innovation is the key”

Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.

Björn Arvidsson: ”Olyckligt att blanda ihop life science och sjukvård”

"Även om life science är morgondagens sjukvård, är det viktigt att inse att dessa två sektorer har olika behov och förutsättningar". Det skriver Björn Arvidsson i en krönika.

Swedish and Ukrainian Medical Product Agencies sign an agreement

The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.

Hajpat genterapibolag går för en spottstyver

Genterapibolaget Bluebird Bio värderades en gång till över 10 miljarder dollar – men säljs nu för en bråkdel av den summan.

SMC lanserar ny elektrisk cylinder för livsmedelsindustrin

Nya HF2A-LEY är framtagen för att möta kraven inom livsmedelsindustrin och passar perfekt i maskiner som utsätts för regelbunden desinfektion och rengöring. Cyl...

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

The US is leaving the WHO

The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.

ZEISS Microscope has been Optimized for Capturing Subcellular Structures and their Dynamics

Live imaging with uniform super-resolution in all spatial dimensions.

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Mavatar AB

Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

HAB Nicolai Johannsen

“Together Stockholm-Uppsala and Medicon Valley can make Scandinavia a leading life science region”

“Denmark, Sweden, Norway and Finland all have national life science strategies, but the Swedish strategy is the only one explicitly emphasizing the Nordic dimen...

Swedish pavilion with healthcare companies at Ukraine fair – “Ukraine is being rebuilt right now”

Private companies and public authorities are both needed in the reconstruction of Ukraine, said Minister for Health Care, Acko Ankarberg Johansson, in her openi...

Accelerate your Research with AI-Powered Image Analysis

Comprehensive eBook from ZEISS.

How to transport hydrogen - the BionicHydrogenBattery

Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.